57/100BBiogen stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Biogen is 258.33, 2.7% above the current price of 251.50. Their targets range from 175.00 to 305.00.
Of the 24 firms that rated Biogen in the past 12 months, 16 rate it buy or strong buy, 7 hold and 1 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 175.00 to 305.00, with an average of 258.33.
| Buy | 16 | |
| Hold | 7 | |
| Sell | 1 |
12-month price target
| Highest target | 305.00 |
| Average target | 258.33 |
| Lowest target | 175.00 |
| Current price | 251.50 |
Biogen price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Biogen price target and rating?
How analysts rate Biogen, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
16 of 24 firms rate it buy now, against 9 of 21 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Biogen analyst upgrades, downgrades and price targets
The latest rating change came on 29 October 2026, when Argus Research upgraded Biogen from Hold to Buy. Its price target is 280.00. The most recent new target came from Piper Sandler on 9 November 2026: 305.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 9 Nov 2026 | Piper Sandler David Amsellem | Reiterated · Overweight | 245.00 → 305.00 | +24.5% | 254.95 |
| 2 Nov 2026 | Guggenheim Yatin Suneja | Reiterated · Buy | 280.00 → 300.00 | +7.1% | 253.62 |
| 29 Oct 2026 | RBC Capital | Reiterated · Outperform | 256.00 → 272.00 | +6.3% | 251.63 |
| 29 Oct 2026 | Wedbush | Reiterated · Neutral | 201.00 → 225.00 | +11.9% | 252.58 |
| 29 Oct 2026 | Argus Research Jasper Hellweg | Upgraded · Hold → Buy | 280.00 | — | 252.41 |
| 29 Oct 2026 | UBS | Reiterated · Buy | 270.00 → 300.00 | +11.1% | 252.31 |
| 29 Oct 2026 | Robert W. Baird | — | 250.00 → 290.00 | +16.0% | 244.05 |
| 12 Oct 2026 | BMO Capital | — | 196.00 → 220.00 | +12.2% | 232.95 |
| 12 Oct 2026 | JP Morgan | Upgraded · Neutral → Overweight | — | — | — |
| 9 Oct 2026 | UBS | Reiterated · Buy | 240.00 → 270.00 | +12.5% | 223.25 |
| 8 Oct 2026 | RBC Capital | Reiterated · Outperform | 260.00 → 256.00 | -1.5% | 219.91 |
| 10 Sept 2026 | Stifel Nicolaus Paul Matteis | — | 242.00 | — | 214.77 |
| 10 Sept 2026 | HSBC | Reiterated · Reduce | 157.00 → 175.00 | +11.5% | 210.73 |
| 3 Sept 2026 | Piper Sandler | Reiterated · Overweight | 225.00 → 245.00 | +8.9% | 222.67 |
| 25 Aug 2026 | RBC Capital | Reiterated · Outperform | 240.00 → 260.00 | +8.3% | 218.12 |
| 13 Aug 2026 | Wolfe Research | Upgraded · Peer Perform → Outperform | 231.00 → 300.00 | +29.9% | 208.87 |
| 30 Jul 2026 | Morgan Stanley Terence Flynn | Reiterated · Equal Weight | 222.00 → 231.00 | +4.1% | 206.50 |
| 30 Jul 2026 | H.C. Wainwright | — | 228.00 → 251.00 | +10.1% | 205.74 |
| 30 Jul 2026 | RBC Capital | Reiterated · Outperform | 242.00 → 240.00 | -0.8% | 204.10 |
| 30 Jul 2026 | UBS | Reiterated · Buy | 185.00 → 240.00 | +29.7% | 204.62 |
| 30 Jul 2026 | Canaccord Genuity | Reiterated · Buy | 230.00 → 248.00 | +7.8% | 209.23 |
| 29 Jul 2026 | Oppenheimer Jay Olson | — | 225.00 → 300.00 | +33.3% | 209.23 |
| 21 Jul 2026 | Guggenheim Yatin Suneja | Reiterated · Buy | 260.00 → 280.00 | +7.7% | 203.03 |
| 13 Jul 2026 | Wedbush | — | 196.00 → 201.00 | +2.6% | 202.05 |
| 13 Jul 2026 | Truist Financial | Upgraded · Hold → Buy | 193.00 → 235.00 | +21.8% | 199.15 |
| 8 Jul 2026 | Morgan Stanley Terence Flynn | Reiterated · Equal Weight | 224.00 → 222.00 | -0.9% | 205.70 |
| 7 Jul 2026 | RBC Capital | Reiterated · Outperform | 227.00 → 242.00 | +6.6% | 208.46 |
| 6 Jul 2026 | HSBC Morten Herholdt | — | 143.00 → 157.00 | +9.8% | 213.26 |
| 18 Jun 2026 | Morgan Stanley | Reiterated · Equal Weight | 206.00 → 224.00 | +8.7% | 198.67 |
| 15 Jun 2026 | Mizuho Securities Salim Syed | Reiterated · Outperform | 236.00 → 221.00 | -6.4% | 200.05 |
| 8 Jun 2026 | Needham | Upgraded · Hold → Buy | 255.00 | — | 195.34 |
| 27 May 2026 | RBC Capital Brian Abrahams | Reiterated · Outperform | 222.00 → 227.00 | +2.3% | 193.08 |
| 15 May 2026 | Piper Sandler | Reiterated · Overweight | 214.00 → 225.00 | +5.1% | 191.37 |
| 30 Apr 2026 | Morgan Stanley | Reiterated · Equal Weight | 200.00 → 206.00 | +3.0% | 188.76 |
| 30 Apr 2026 | RBC Capital Brian Abrahams | Reiterated · Outperform | 233.00 → 222.00 | -4.7% | 190.78 |
| 30 Apr 2026 | Wedbush | Reiterated · Neutral | 187.00 → 196.00 | +4.8% | 194.38 |
| 30 Apr 2026 | Guggenheim | Reiterated · Buy | 246.00 → 260.00 | +5.7% | 194.38 |
| 22 Apr 2026 | UBS | Upgraded · Neutral → Buy | — | — | — |
| 20 Apr 2026 | Wells Fargo Mohit Bansal | Upgraded · Equal Weight → Overweight | 200.00 → 250.00 | +25.0% | 177.35 |
| 14 Apr 2026 | Piper Sandler | Upgraded · Neutral → Overweight | 177.00 → 214.00 | +20.9% | 176.37 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Equal Weight | 190.00 → 200.00 | +5.3% | 173.48 |
| 19 Feb 2026 | Barclays Emily Field | — | 185.00 | — | 192.08 |
| 11 Feb 2026 | Mizuho Securities | — | 236.00 | — | 188.99 |
| 10 Feb 2026 | Wedbush Laura Chico | Reiterated · Neutral | 187.00 | — | 192.72 |
| 9 Feb 2026 | Wolfe Research | — | 215.00 → 231.00 | +7.4% | 196.00 |
| 9 Feb 2026 | RBC Capital | Reiterated · Outperform | 213.00 → 233.00 | +9.4% | 195.93 |
| 9 Feb 2026 | Wolfe Research | — | 215.00 | — | 195.45 |
| 9 Feb 2026 | Truist Financial Danielle Brill | Reiterated · Hold | 190.00 → 193.00 | +1.6% | 201.18 |
| 9 Feb 2026 | Canaccord Genuity | Reiterated · Buy | 265.00 → 230.00 | -13.2% | 201.18 |
| 9 Feb 2026 | Piper Sandler | Reiterated · Neutral | 157.00 → 177.00 | +12.7% | 201.18 |
Biogen EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Biogen's EPS to grow 27.6% a year until 2028. Over the last 5 years it fell 18.7% a year, and over the last 3 years it fell 24.9%.
Analysts expect Biogen's revenue to grow 4.0% a year until 2028. Over the last 5 years it fell 6.0% a year, and over the last 3 years it fell 0.9%.
Revenue
EPS
Does Biogen beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 17.7% off the result, either way, and their revenue estimate 5.5%, over the last 12 quarters.
- EPS beats
- 97 / 136
- Revenue beats
- 90 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +16.6%
- Since
- March 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 28 Oct 2026 | 1.99 | 2.62 | +31.7% | 2.63B | 2.80B | +6.4% |
| Q2 FY2026 | 29 Jul 2026 | 2.94 | 3.60 | +22.4% | 2.46B | 2.74B | +11.2% |
| Q1 FY2026 | 29 Apr 2026 | 3.05 | 3.57 | +17.0% | 2.29B | 2.48B | +8.4% |
| Q4 FY2025 | 6 Feb 2026 | 1.63 | 1.99 | +22.1% | 2.20B | 2.28B | +3.5% |
| Q3 FY2025 | 30 Oct 2025 | 3.88 | 4.81 | +24.0% | 2.34B | 2.45B | +4.9% |
| Q2 FY2025 | 31 Jul 2025 | 3.90 | 5.47 | +40.3% | 2.33B | 2.65B | +13.6% |
| Q1 FY2025 | 1 May 2025 | 2.90 | 3.02 | +4.1% | 2.23B | 2.43B | +8.8% |
| Q4 FY2024 | 12 Feb 2025 | 3.43 | 3.44 | +0.3% | 2.41B | 2.45B | +1.9% |
| Q3 FY2024 | 30 Oct 2024 | 3.77 | 4.08 | +8.2% | 2.43B | 2.47B | +1.3% |
| Q2 FY2024 | 1 Aug 2024 | 4.07 | 5.28 | +29.7% | 2.39B | 2.35B | -1.6% |
| Q1 FY2024 | 24 Apr 2024 | 3.47 | 3.67 | +5.8% | 2.31B | 2.29B | -0.8% |
| Q4 FY2023 | 13 Feb 2024 | 3.16 | 2.95 | -6.6% | 2.47B | 2.39B | -3.2% |
Biogen stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Biogen's earnings keep growing at the 6.3% a year analysts expect to FY2028, it would earn about 20.74 a share in FY2030. At the P/E it has traded at over the last five years (13.2 to 32.3) that is 273.85 to 669.12 a share, or 423.02 at its average P/E of 20.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 12.50 | 165.12 | 255.06 | 403.44 |
| FY2027 | 16.24 | 214.39 | 331.17 | 523.83 |
| FY2028 | 18.36 | 242.42 | 374.47 | 592.33 |
| FY2029 (extrapolated) | 19.51 | 257.66 | 398.00 | 629.55 |
| FY2030 (extrapolated) | 20.74 | 273.85 | 423.02 | 669.12 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 6.3% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (13.2, 20.4, 32.3).
Is Biogen stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Biogen's P/E of 106.6 is near the top of its 5-year range (10.1 to 108.0, median 17.6). It is within 5% of its 5-year high. Analysts expect faster growth than in recent years, which can explain part of the high P/E. Growing 27.6% a year, Biogen earns a P/E of 25.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 15.74, a fair value of 393.61; the price, 251.50, is 36.1% below it. Its forward P/E, on the consensus for FY2026, is 20.1.
Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 18.8 and 31.3). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 106.57
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.55
- Five-year P/E range
- 10.1 – 108.0
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 20.11
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 16.96
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +2.7%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.